Civil society organisations urge govt to scrap animal testing in biosimilar development

Civil society organizations are urging the health ministry to eliminate animal studies in biosimilar development to lower production costs and expedite the process. They emphasize that removing these tests will enhance affordability and uphold ethical standards. The government is revising biosimilar regulations, potentially restricting animal use and prioritizing in-vitro studies, aligning with global standards to ensure safety and efficacy.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PenTDGJ
via IFTTT

Read More

PLI scheme for bulk drugs led to import savings of Rs 1,362 cr: Govt

India's PLI scheme for bulk drugs is showing positive results. It has reduced pharma raw material imports by Rs 1,362 crore until March 2025. The scheme spurred domestic manufacturing and exports. Investment under the scheme has already surpassed initial commitments. The government has also initiated a PLI Scheme for Pharmaceuticals with a total budgetary outlay of Rs 15,000 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QJzVsyj
via IFTTT

Read More

Godavari Biorefineries secures Chinese patent for breakthrough anti-cancer molecule

Godavari Biorefineries received a patent from China for its new anti-cancer molecule. The China National Intellectual Property Administration granted the patent. Sathgen Therapeutics, Godavari's biotech division, developed the molecule. The molecule, HYDROXY-1,4-NAPHTHALENEDIONE, shows promise in fighting cancer. In vitro studies showed it inhibits cancer and cancer stem cells. It is effective against breast and prostate cancer cells.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fey3ca6
via IFTTT

Read More

Obesity lab: India becomes ground zero for weight-loss drug race

India is emerging as a key player in the global weight management industry, driven by a rising obesity crisis and the impending patent expirations of blockbuster drugs. Pharmaceutical giants are launching innovative anti-obesity medications, while Indian companies gear up to produce affordable generic versions. Government support and incentives further position India as a major exporter of these crucial medications.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FsK6H18
via IFTTT

Read More

ADIA signs a definitive agreement to invest $200 million in medical devices firm Meril

Abu Dhabi Investment Authority (ADIA) is set to invest $200 million for a 3% stake in medical device maker Meril, valuing the company at $6.6 billion. This investment, pending CCI approval, will support Meril's growth and research efforts.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SehyA24
via IFTTT

Read More

Abu Dhabi Investment Authority to buy 3% stake in Micro Life Sciences for $200 mn

Abu Dhabi Investment Authority (ADIA) is set to acquire a 3% stake in the Indian medical device company, Micro Life Sciences Pvt Ltd (Meril), for USD 200 million. This investment values Meril at USD 6.6 billion, pending regulatory approval from the Competition Commission of India (CCI). Meril plans to use the funds to accelerate growth and strengthen clinical research.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rFMbOcD
via IFTTT

Read More

Brookfield, EQT close in on Gland Pharma, but rising stock a pain

The Chinese parent has diversified investments that range from healthcare to football clubs, asset management, banks, estate, hospitality, fashion and industrials. The conglomerate has a presence across the pharma value chain from manufacturing to diagnostics and medical devices. Shanghai Fosun Pharmaceutical Co. had acquired an 86% stake in Gland Pharma in 2016 from KKR for a record deal value of $1.26 billion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XMPWGYU
via IFTTT

Read More

Zydus Life's plans for cancer biosimilar hit a legal hurdle

The Delhi High Court has granted an interim injunction against Zydus Lifesciences, an Ahmedabad-based drug maker, following a patent infringement case filed by Bristol Myers Squibb concerning its anticancer drug Opdyta (nivolumab).

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Q40EjHC
via IFTTT

Read More

Dr Reddy's gets seven observations from USFDA for Andhra plant

Dr Reddy's Laboratories faces scrutiny. The USFDA issued a Form 483 after inspecting their Srikakulam facility. The inspection, which occurred in July 2025, revealed seven observations. These observations relate to potential violations of the Food, Drug and Cosmetic Act. Dr Reddy's plans to address these concerns promptly. The company aims to resolve the issues within the given timeframe.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5DHes8o
via IFTTT

Read More

Development of indigenous multi-stage Malaria vaccine 'AdFalciVax' is underway

India is developing a new malaria vaccine. The Indian Council of Medical Research is leading the effort. The vaccine is called AdFalciVax. It targets two stages of the malaria parasite. Preclinical data shows excellent efficacy. The vaccine could prevent infection and reduce transmission. ICMR plans to license the technology to manufacturers. This aims to make the vaccine widely available.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KJ75uly
via IFTTT

Read More

Mind your posture: Doctors cite long hours in front of screen for increasing lifestyle diseases

Young professionals are increasingly facing lifestyle ailments due to prolonged sitting and screen time, leading to a 30-40% rise in muscular, spinal, eye, heart, and mental health disorders. The pressure to stay relevant in an AI-driven workplace exacerbates these issues, causing conditions like Tech Neck and Digital Fatigue Syndrome.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NRZwo7U
via IFTTT

Read More

New dilemma looms for India’s private hospitals: More beds, but few can lie in them

India's private hospital sector faces a potential overcapacity in major cities due to significant upcoming bed additions, even as smaller towns lack sufficient beds. While demand for quality healthcare grows, driven by rising incomes and insurance coverage, analysts caution that this expansion could strain profitability.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DpnW9w0
via IFTTT

Read More

Sprays, pills, creams...ooh, aah, ouch? India’s pain market is now a Rs 16,000 cr giant

India’s pain relief market has exploded post-pandemic, doubling to nearly ₹16,000 crore in just five years. From gels and sprays to pills like Dolo and Zerodol, pain meds are now a daily fix for everything from gym soreness to chronic stress. The shift is lifestyle-driven and increasingly normalised, but experts warn against unchecked self-medication. As the over-the-counter space booms, driven by awareness and ease of access, the line between relief and risk is getting worryingly thin.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2tuEaO7
via IFTTT

Read More

Central drugs laboratories find 55 samples to be 'not of standard quality' in June

In June 2025, central drugs laboratories discovered 55 drug samples failing quality standards, while state labs found 130 similarly substandard. The CDSCO regularly posts lists of these and spurious drugs. Additionally, one drug sample each from Bihar and Delhi, and two from Telangana, were identified as spurious, prompting investigations and regulatory action.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vnuZJlp
via IFTTT

Read More

Kenvue ties up with API to launch India's first Cough Clinics

Kenvue, makers of Benadryl, introduces 'Cough Clinics' in partnership with the Association of Physicians of India. This initiative aims to establish ten Centers of Excellence across India. These clinics will enhance healthcare professionals' knowledge of cough evaluation. The goal is to promote science-backed approaches to treatment. The clinics will offer specialized training and tools for physicians.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/H1E9tSQ
via IFTTT

Read More

Torrent Pharma seeks CCI nod to acquire majority stake in JB Chemicals for Rs 19,500 crore

Torrent Pharmaceuticals is looking to acquire J B Chemicals and Pharmaceuticals. The deal is worth Rs 19,500 crore. The company has sought clearance from the Competition Commission of India. After the deal, Torrent will become India's second most valued pharma company. Torrent will acquire a 46.39 per cent stake from Tau Investment. It will also buy 2.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BFv9ajx
via IFTTT

Read More

Glenmark Pharma will turn cash positive with AbbVie's licensing deal: S&P

S&P Global Ratings projects Glenmark Pharmaceuticals will achieve a net cash positive position following its licensing agreement with AbbVie Inc. This deal, concerning ISB 2001, is expected to significantly strengthen Glenmark's financial standing and liquidity, reversing a previous net debt.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ibjoY94
via IFTTT

Read More

CORONA Remedies acquires 7 brands from Bayer's pharma division in India

CORONA Remedies has bought seven brands from Bayer's pharmaceutical unit in India. The deal includes Noklot for heart patients. Women's health brands like Fostine and Ovidac are also part of the acquisition. This move allows CORONA Remedies to enter a new heart treatment area. It also strengthens their position in women's healthcare.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0AdBOax
via IFTTT

Read More

Glenmark Pharmaceuticals targets 70% branded portfolio by 2030, boosts focus on novel drugs

Glenmark Pharmaceuticals is transitioning into an innovation-driven company over the next 4-5 years, emphasizing its novel drug portfolio and strengthening its branded business. By 2030, the company aims for 70% of its revenue to come from branded products, focusing on dermatology, respiratory, and oncology. A recent deal with AbbVie for its cancer drug ISB 2001 highlights this strategic shift.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ym1bgjE
via IFTTT

Read More

Domestic med-tech companies flag security threat from Chinese devices

Indian medical tech leaders have voiced concerns to the government regarding the security risks associated with importing Chinese healthcare devices. They highlighted potential misuse for surveillance, cyberattacks, and data breaches, urging stricter scrutiny and measures to prevent rerouting via other countries. Manufacturers also seek streamlined regulations and policy support to boost domestic production and achieve self-reliance.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yDKMJ4j
via IFTTT

Read More

Biocon Biologics gets USFDA nod for diabetes medication

Biocon Biologics has secured USFDA approval for Kirsty. Kirsty is an interchangeable biosimilar to NovoLog, used for diabetes treatment. It is a rapid-acting insulin analog. The medication will be available in prefilled pens and vials. This approval expands Biocon's insulin portfolio. Kirsty has been available in Europe and Canada since 2022. The US market for Insulin Aspart is significant.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/t5qvzBc
via IFTTT

Read More

200% or more? Trump hints at 'very high tariffs' on pharma cos by August 1, says deal with India most likely

US President Trump had earlier suggested pharmaceutical tariffs could reach 200% after a year, incentivizing domestic manufacturing. On Tuesday, he said that an agreement with India was among the most likely.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/68QMApb
via IFTTT

Read More

Manipal Hospitals borrows Rs 5,300 crore from global banks to fund Sahyadri acquisition

Manipal Hospitals is securing ₹5,300 crore from foreign banks. This funding supports its acquisition of Sahyadri Hospitals. Deutsche Bank, Barclays, MUFG, SMBC, and DBS Bank are providing the debt. The total deal is around ₹5,900 crore. Manipal will issue bonds maturing in two years. An IPO is planned for 2026.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0s8CIQY
via IFTTT

Read More

HLL Lifecare reports annual condom production of 221.7 cr

HLL Lifecare, a Kerala-based PSU, produces 221.7 crore condoms annually, solidifying its position as a leading global manufacturer. With eight factories across India, HLL significantly contributes to the nation's family welfare programs. Established in 1966 to address population growth, HLL has expanded beyond contraceptives, producing diagnostic kits, pharmaceuticals, and Ayurvedic medicines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Aypom2c
via IFTTT

Read More

Govt revises prices of 71 medicines, including those for diabetes and infections: Check new rates

The National Pharmaceutical Pricing Authority (NPPA) has revised the prices of 71 essential drug formulations, encompassing treatments for metastatic breast cancer, diabetes, peptic ulcers, and severe infections. This revision aims to ensure affordability and accessibility of these crucial medicines. Retailers are now mandated to display the updated price lists for transparency and consumer awareness.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/V3DSHNF
via IFTTT

Read More

Marengo Hospitals lines up ₹150 cr for western foray

Marengo Asia Healthcare, supported by Samara Capital and others, is set to expand into Maharashtra and Rajasthan with a ₹150 crore investment. The multi-specialty hospital platform aims to double its bed capacity from 1,500 to 3,000 by next year through strategic acquisitions and expansion of existing facilities, solidifying its position as a top healthcare leader in North and West India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Jy5v3Ix
via IFTTT

Read More

Temasek building on India strategy with special focus on healthcare

Singapore's Temasek is significantly expanding its healthcare investments in India, prioritizing scalable and specialized platforms. Their recent backing of Manipal Hospitals' acquisition of Sahyadri Group demonstrates this strategy, creating a stronger presence in western India. Temasek aims to enhance accessibility and quality in underserved markets, focusing on profitable growth and strategic acquisitions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ze9VfyB
via IFTTT

Read More

Sun Pharma settles litigation with Incyte Corp

Sun Pharmaceutical Industries has reached a settlement agreement with Incyte Corporation concerning Leqselvi, a drug for severe hair loss, leading to the dismissal of pending litigation in the US. Incyte has granted Sun a non-exclusive license for oral deuruxolitinib for specific non-oncology indications, including alopecia areata, in the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qHV6xcw
via IFTTT

Read More

Aayush Wellness expands nutraceutical product portfolio

Aayush Wellness introduced a new capsule for cognitive function. The company expands its nutraceutical line to address memory and focus issues. They aim to tap into the growing Indian nutraceutical market. Naveena Kumar highlights brain health's importance. Aayush Wellness recently entered tele-consultation and diagnostic testing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gzFLkZp
via IFTTT

Read More

Phase-3 clinical trial enrolment for India's first dengue vaccine to be completed by October: ICMR

India's DengiAll vaccine trial is nearing completion. ICMR scientists anticipate enrolling 10,500 participants by October across 20 Indian centers. The phase III trial assesses the Panacea Biotec's one-shot dengue vaccine. Initial trials showed no safety concerns. Participants will be monitored for two years to evaluate efficacy. This is a crucial step as India currently lacks a licensed dengue vaccine.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/54vZpRP
via IFTTT

Read More

Cipla eyes entry into India's weight management market amid rising demand and global competition

Cipla is set to enter India's weight management market, addressing the increasing demand for obesity solutions, while also strengthening its central nervous system portfolio through strategic in-licensing deals and acquisitions, particularly in ADHD and Parkinson's disease. The company is also focusing on innovation-led solutions to combat antimicrobial resistance and aims to be a global, patient-centric healthcare leader.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CnbNVQU
via IFTTT

Read More

India's Ayush 'innovations' featured in WHO's brief on AI in traditional medicine

The WHO has lauded India's integration of Artificial Intelligence (AI) with traditional medicine systems like Ayush, acknowledging the country's efforts in a technical brief. This recognition follows India's proposal, leading to WHO's roadmap for AI in traditional medicine. India is using AI to advance Ayush systems through digital platforms, preserving traditional knowledge and promoting global healthcare integration.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dphJrXa
via IFTTT

Read More

India pharma, healthcare revenue to grow steadily in Q1FY26E; EBITDA margins under pressure: Report

Indian pharma and healthcare sector will witness steady revenue growth in the first quarter of the Financial Year 2026 (Q1FY26E), but concerns loom as EBITDA margins are expected to decline amid rising input costs and pricing pressures, according to a report by HDFC Securities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3kq04eV
via IFTTT

Read More

Wockhardt exits US generics biz to focus on drug discovery

Wockhardt is set to exit its loss-making US generics business to prioritize innovation, focusing on new antibiotic drug discovery and its biologics portfolio in insulin. The company has initiated voluntary liquidation for its US subsidiaries under Chapter 7 of the US Bankruptcy Code. This strategic shift allows Wockhardt to concentrate on high-impact areas and long-term value creation through scientific advancements.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rc26b7Z
via IFTTT

Read More

Biosimilars to usher new growth, lead $1 trillion drug exports by 2030

India's pharmaceutical industry is targeting $1 trillion in drug exports by 2030, with biosimilars expected to be a major growth driver. The biosimilars market could exceed $60 billion by 2030, supported by Indian firms investing in biologics and advanced markets. Achieving this ambitious goal requires collaboration and a focus on innovation-driven categories.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pyYO9Eq
via IFTTT

Read More

Pharmexcil flags export disruption risk due to COPP mandate; seeks urgent review

Pharmaceutical Export Promotion Council of India wants Central Drugs Standard Control Organisation to rethink its online Certificate of Pharmaceutical Product submission rule. The council fears this could hurt India's drug exports, especially to Rest of World markets. They worry about delays in approvals. Pharmexcil has asked the Ministry of Health & Family Welfare and CDSCO to talk with exporters.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WDQKnfL
via IFTTT

Read More

7 daily habits that silently damage your kidneys

Your kidneys quietly work to filter waste and balance your body’s fluids—but some everyday habits may be putting them at risk without you realising it. Here are 7 common behaviours that could be harming your kidney health over time.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NcHa5Ke
via IFTTT

Read More

Adani to create world-class, affordable, AI-first healthcare ecosystems

Gautam Adani unveiled plans for an AI-driven healthcare ecosystem in India, emphasizing affordability and scalability. He highlighted the need for a system-wide redesign, citing low back pain as a major disability. Adani announced Adani Healthcare Temples with Mayo Clinic's guidance, focusing on integrated care, technology, and skilled professionals to address healthcare gaps.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5sCUYaj
via IFTTT

Read More

PGIMER doctors perform India's first robot-assisted vasovasostomy

Doctors at PGIMER Chandigarh have achieved a groundbreaking feat by successfully performing India's first robot-assisted vasovasostomy. The urology team, led by Dr. Aditya Prakash Sharma, used the da Vinci Surgical System for enhanced precision in the male infertility surgery. This innovative approach offers new hope for couples seeking natural conception after vasectomy, marking a significant advancement in andrology and microsurgery.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hQFxpN1
via IFTTT

Read More

Ichnos Glenmark, AbbVie ink USD 2-bn licensing deal for commercialisation of investigational asset

Glenmark Pharmaceuticals has entered into a significant agreement with AbbVie to commercialize its investigational drug, ISB 2001, targeting cancer and autoimmune diseases. The deal, potentially worth up to USD 2 billion, grants AbbVie exclusive rights in major markets, while Glenmark will focus on emerging markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MqsJ2Ro
via IFTTT

Read More

Lupin signs $50 million licensing deal with Zentiva to commercialise Certolizumab Pegol across global markets

Lupin Ltd has partnered with Zentiva Group to commercialize its biosimilar 'Certolizumab Pegol' across global markets. The agreement grants Zentiva commercialisation rights outside the US and Canada, primarily in Europe and CIS markets. Lupin will receive up to USD 50 million in milestone payments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/c5ZStIC
via IFTTT

Read More

Granules India recalls 33,000 bottles of blood lowering medication in US

Granules India is recalling over 33,000 bottles of Metoprolol Succinate, a generic blood pressure medication, in the US due to manufacturing issues. The USFDA reported that the India-produced lot failed to meet dissolution specifications during stability studies. This Class II recall, initiated on June 24, indicates a potential for temporary or medically reversible health consequences.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aPLj7Zr
via IFTTT

Read More

Pills & Profits: Can India's pharma sector handle Trump's planned 200% tariff dose?

India's pharma sector faces a potential challenge. The US considers high tariffs on drug imports. This could hurt Indian companies' profits and competitiveness. It might also raise medicine prices in America. India relies heavily on the US for pharma exports. Companies may need to explore new markets like Europe and Southeast Asia. The news impacted Indian stock markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3eP5Za6
via IFTTT

Read More

Pharma lobby flags 'cumbersome' export rule, seeks change

Pharma lobby groups are urging for changes to the centralized no-objection certification (NOC) for drug exports due to a significant export decline. The requirement for approvals from importing countries or Indian regulators has increased trade diversions. Industry experts are calling for a review of the provision, citing burdens on exporters and potential stifling of innovation, especially for MSMEs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8D1GLtI
via IFTTT

Read More

Nectar to sell API, formulations & menthol biz to Ceph Lifesciences for Rs 1,290 cr

Nectar Lifesciences will sell its active pharmaceutical ingredients, formulation, and menthol business assets to Ceph Lifesciences for ₹1,290 crore. This strategic move involves a Business Transfer Agreement for the core API and formulation business at ₹1,270 crore and an Asset Purchase Agreement for the menthol business at ₹20 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ivWj9Rx
via IFTTT

Read More

Aster DM Healthcare sets sights on smaller cities to expand play, grab top spot

Aster DM Healthcare, after merging with Quality Care India, aims to become India's largest healthcare chain, surpassing Apollo Hospitals. Fueled by Blackstone's backing, Aster plans to increase bed capacity to 13,600 and expand into central India. The company anticipates improved margins through supply chain optimization and increased occupancy, targeting a 23-24% EBITDA margin.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CVQ36Z0
via IFTTT

Read More

Delhi HC upholds order to restrain Rajasthan Aushdhalaya from making and selling medicines under Liv-333 name

The Delhi High Court has upheld a previous order restraining Rajasthan Aushdhalaya from selling medicines under the name Liv-333 or similar names, due to trademark infringement of Himalaya's Liv.52. The court found Rajasthan Aushdhalaya's adoption of 'Liv-333' as intentionally similar to capitalize on Himalaya's established reputation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Bo5pOHQ
via IFTTT

Read More

Indian Medical Association opposes decision to allow homeopaths to prescribe modern medicines post pharma course

The Indian Medical Association (IMA) has strongly criticised the Maharashtra Medical Council's (MMC) recent notification allowing homeopaths to prescribe modern medicines after a brief pharmacology course. IMA views this as misleading to patients and a dilution of modern medical practices. They highlight existing legal challenges and a stay order from the Bombay High Court, seeking expedited resolution.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/q7HO9ik
via IFTTT

Read More

Biocon Biologics gets UK MHRA nod for biosimilars Vevzuo, Evfraxy

Biocon Biologics Ltd has achieved a significant milestone. It has secured marketing authorizations in the UK for Vevzuo and Evfraxy. These are biosimilars of Denosumab. Vevzuo addresses skeletal events in adults with advanced malignancies. Evfraxy treats osteoporosis and bone loss. This approval follows a similar authorization from the European Commission. It allows commercialization across the EU and EEA.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CScevDN
via IFTTT

Read More

Union Health Minister JP Nadda, Delhi CM Rekha Gupta flag off Ayushman Bharat registration vans in New Delhi

Union Minister JP Nadda and Delhi CM Rekha Gupta launched Ayushman Bharat registration vans in New Delhi. Nadda criticized AAP for not utilizing allocated funds for the scheme. He praised Ayushman Arogya Mandir, contrasting it with AAP's Mohalla Clinics. Rekha Gupta and ministers inaugurated Ayushman Arogya Mandirs in Delhi. Ashish Sood distributed Ayushman Bharat cards to senior citizens in Janakpuri.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pz4MjSQ
via IFTTT

Read More

DRDO, AIIMS-Rishikesh ink MoU for clinical trials in field of biomedical devices

DRDO's Defence Institute of Physiology and Allied Sciences (DIPAS) and AIIMS, Rishikesh, have partnered to conduct clinical trials and advanced research. The collaboration aims to develop biomedical devices and supplements enhancing human performance in extreme environments. This joint effort will focus on creating products and technologies to mitigate the adverse effects of such environments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/R4XrpWa
via IFTTT

Read More

Niti to review concerns over pharma quality

Niti Aayog is addressing growing quality concerns in India's pharmaceutical industry by convening industry experts for discussions. The aim is to analyze the current state, understand challenges, and improve the quality of Indian pharmaceutical products to meet global standards. A meeting chaired by VK Paul will propose recommendations to ensure alignment with international regulations and patient safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GmwUWSu
via IFTTT

Read More

Lupin launches Ipratropium Bromide nasal spray in US

Lupin Ltd has introduced Ipratropium Bromide nasal spray in the US, available in 0.03% and 0.06% strengths. These sprays, bioequivalent to Boehringer Ingelheim's Atrovent, target rhinorrhea associated with allergies, nonallergic rhinitis, and the common cold. The annual sales for Ipratropium Bromide nasal solution (Atrovent) in the US were approximately USD 63 million, according to IQVIA MAT May 2025 data.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PCLqjzw
via IFTTT

Read More

CBI searches premises of Pharmacy Council of India chief in corruption case

The CBI has booked Pharmacy Council of India President Montu M. Patel for alleged corruption and irregularities in pharmacy college approvals, conducting searches at his premises. Investigations revealed manipulated inspections, favouritism towards specific institutions, and electoral manipulation before Patel's presidential election. Approvals were granted despite negative reports, with evidence of bribery and infrastructural deficiencies in several colleges across multiple states.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VEXimKg
via IFTTT

Read More

Hassan heart attack death cases: India’s top drugmakers rally behind Covid vaccines

Amid over 20 sudden heart attack deaths in Karnataka’s Hassan district, leading drugmakers have defended Covid vaccines on social media. Industry leaders including Dilip Shanghvi, Pankaj Patel, Satish Reddy, and Samir Mehta stressed there is no scientific link between the deaths and vaccination. The Karnataka health department has formed an expert panel to investigate. The Indian Vaccine Manufacturers Association and the Indian Pharmaceutical Alliance urged the public to trust India’s vaccine safety and rigorous approval process.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yrUVkHO
via IFTTT

Read More

COVID-19 vaccines well-documented, rigorously tested as per regulatory processes: IPA

The Indian Pharmaceutical Alliance (IPA) refuted claims linking COVID-19 vaccines to heart attack deaths, emphasizing their rigorous testing and crucial role in combating the pandemic. IPA Secretary General Sudarshan Jain highlighted the Indian pharmaceutical industry's knowledge-driven nature and its significant contribution to global vaccine production, accounting for 60% of the world's supply.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VxE9BGk
via IFTTT

Read More

Karnataka CM's remarks on covid vaccines 'factually incorrect,' says Biocon chief Kiran Mazumdar-Shaw

Kiran Mazumdar-Shaw refuted Karnataka CM Siddaramaiah's claim. Siddaramaiah linked covid-19 vaccines to heart attack deaths in Hassan. Shaw stated the vaccines followed rigorous safety protocols. She said the vaccines saved lives. The Union Health Ministry dismissed Siddaramaiah's statement. Studies show no link between vaccines and sudden deaths. The ministry cited various factors for cardiac deaths.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/orBn0vj
via IFTTT

Read More

Delhi HC seeks regulator's reply after PIL questions Ozempic, Mounjaro nod

The Delhi High Court has instructed India's drug regulator to address concerns about the approval process for drugs like Ozempic and Mounjaro. A public interest litigation raised questions about safety data and clinical trials. The court wants the regulator to consult experts and manufacturers. Ozempic is available in the grey market, though not officially sold in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3fn2M7o
via IFTTT

Read More

Auriga Research, SFRI ink pact to advance clinical research, AI-driven support for healthcare industry

Auriga Research partners with San Francisco Research Institute. The collaboration focuses on global clinical research. It will promote AI-integrated healthcare solutions. The partnership aims to expand access to wellness products in India, the US, and Africa. SFRI will support regulatory strategy and commercial partnerships. Both organizations will expand their Research Training Program.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xCXdjrv
via IFTTT

Read More

Cipla in talks to add new customers for its China factory, executive says

Indian pharmaceutical giant Cipla is exploring at least two new overseas markets for products made at its Chinese manufacturing plant, as it grapples with limited production capacity in India. The company began producing inhalation respule products at its Jiangsu facility in 2024 to supply the U.S., and is now in talks with other countries to expand exports.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eEWsRNJ
via IFTTT

Read More

Biocon eyes Canadian bonanza from generics of weight-loss 'super-drugs' Ozempic and Wegovy

Biocon Ltd. is set to seek regulatory approvals for generic versions of Novo Nordisk's Ozempic and Wegovy, targeting key markets like Canada, where patents expire next year. Managing Director Siddharth Mittal sees Canada as a prime opportunity, aiming for potential approval in 2026.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SAtE7h3
via IFTTT

Read More